Skip to main content
SMO ClinPlus CO., LTD. logo

SMO ClinPlus CO., LTD. — Investor Relations & Filings

Ticker · 301257 ISIN · CNE100005CP8 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 482 across all filing types
Latest filing 2025-07-21 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 301257

About SMO ClinPlus CO., LTD.

https://www.smo-clinplus.com

SMO ClinPlus CO., LTD. is a professional Site Management Organization (SMO) providing comprehensive clinical trial site management services. The company specializes in supporting pharmaceutical, biotechnology, and medical device developers throughout the clinical development lifecycle. Core services include the provision of Clinical Research Coordinators (CRCs), site feasibility assessments, patient recruitment and retention strategies, and clinical trial data management. ClinPlus facilitates the execution of clinical trials by managing administrative and operational tasks at research sites, ensuring compliance with Good Clinical Practice (GCP) and regulatory requirements. With an extensive network of partner hospitals and research institutions, the company streamlines the clinical research process, enhances data quality, and accelerates project timelines for domestic and international sponsors.

Recent filings

Filing Released Lang Actions
北京国枫（上海）律师事务所关于普蕊斯（上海）医药科技开发股份有限公司2025第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality of a company's 2025 second extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or performance data, nor is it a report of financial results or management discussion. It is a legal opinion on the meeting process and voting results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3192 characters, which is relatively short but contains detailed voting results and legal opinion on the meeting, not just an announcement of a report publication. Therefore, the best fit is DVA.
2025-07-21 Chinese
关于召开2025年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2025 second extraordinary general meeting of shareholders for 普蕊斯（上海）医药科技开发股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be voted on, registration details, and attachments such as proxy forms and voting instructions. There is no financial data, earnings information, or audit content. The document is a formal announcement inviting shareholders to participate in the meeting and vote on proposals. It is not a report of voting results, nor a management or financial report. The content fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document length is 4210 characters, which is consistent with a detailed meeting notice and proxy materials rather than a full report or announcement of results.
2025-07-04 Chinese
第三届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 普蕊斯（上海）医药科技开发股份有限公司 regarding decisions made at their 13th meeting of the third Supervisory Board. It details approval of proposals related to asset acquisition and financial assistance, with voting results and references to further shareholder meeting approvals. The document is short (1335 characters), formal, and focused on board meeting resolutions rather than financial data or report publication. It does not contain financial statements, earnings data, or audit information. It is not a report itself but an announcement of board decisions. Therefore, it fits best under Board/Management Information (MANG).
2025-07-04 Chinese
关于向拟参股公司提供财务资助的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 普蕊斯（上海）医药科技开发股份有限公司 regarding the company's plan to provide financial assistance (财务资助) to a prospective investee company, 上海和立置业有限公司. It details the amount, terms, board and supervisory approvals, risk analysis, and related opinions. The document is structured as a formal announcement with no comprehensive financial statements or detailed financial performance analysis. It is not an annual or interim report, audit report, or earnings release. It is not a call transcript or investor presentation. The document is a regulatory announcement about a capital financing activity (financial assistance to a related company) and includes board meeting resolutions and approvals. Given the content and nature, it fits best under Capital/Financing Update (CAP). The document length is about 4256 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2025-07-04 Chinese
华泰联合证券有限责任公司关于普蕊斯（上海）医药科技开发股份有限公司向拟参股公司提供财务资助的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Huatai United Securities Co., Ltd. regarding financial assistance provided by Puris (Shanghai) Pharmaceutical Technology Development Co., Ltd. to an intended investee company. It includes comprehensive information about the financial assistance, the investee company, financial data, risk analysis, board and supervisory opinions, and the sponsor's verification opinion. The document is not a brief announcement but a substantive report on the financial assistance matter, including financial figures and risk assessments. It does not fit categories like announcement, proxy, or regulatory filings. It is a specialized report related to financial assistance and internal corporate governance and oversight. Given the content and nature, the best fitting category is Regulatory Filings (RNS) as it is a regulatory disclosure document that does not fit other specific categories like capital update or management information. The document length is 4085 characters, which is under 5000, but the content is substantive and not merely an announcement of a report publication, so it is not RPA. Therefore, the classification is RNS with high confidence.
2025-07-04 Chinese
关于参与竞拍和立置业部分股权及相应债权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by 普蕊斯（上海）医药科技开发股份有限公司 regarding its intention to participate in a public auction to acquire 45% equity and corresponding debt of 上海和立置业有限公司, which owns an office building. The document includes background, transaction overview, financial data, legal and regulatory references, and the need for shareholder approval. It is a formal disclosure about a capital investment transaction involving equity acquisition and asset purchase, with no indication of it being a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive transaction details and financial data. The document fits best under Capital/Financing Update (CAP) as it concerns company fundraising and capital structure changes through equity acquisition and related financing arrangements.
2025-07-04 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.